The allogeneic graft-versus-cancer effect

British Journal of Haematology

Volumn 147, Issue 5, 2009, Pages 614-633

  Ringdén, Olle ^a   Karlsson, Helen ^a   Olsson, Richard ^a   Omazic, Brigitta ^a   Uhlin, Michael ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bone marrow transplantation immunology; Haematopoetic stem cell transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; CYCLOSPORIN; GAMMA INTERFERON; GANCICLOVIR; IMATINIB; INTERLEUKIN 2; METHOTREXATE; PEPTIDE VACCINE; RITUXIMAB; T LYMPHOCYTE RECEPTOR; TACROLIMUS; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER RELAPSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DONOR; DOSE RESPONSE; DRUG MEGADOSE; GERIATRIC CARE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOTHERAPY; LEUKEMIA; LYMPHOMA; MYELOMA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; SUICIDE GENE;

GRAFT VS LEUKEMIA EFFECT; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KILLER CELLS, NATURAL; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME;

EID: 70449516435     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07886.x     Document Type: Review

References (243)

1. Akpek, G., Ambinder, R.F., Piantadosi, S., Abrams, R.A., Brodsky, R.A., Vogelsang, G.B., Zahurak, M.L., Fuller, D., Miller, C.B., Noga, S.J., Fuchs, E., Flinn, I.W., O'Donnell, P., Seifter, E.J., Mann, R.B. Jones, R.J. (2001) Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. Journal of Clinical Oncology, 19, 4314 4321.
2. Anderson, L.D., Savary, C.A., Jr., Mullen, C.A. (2000) Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease. Blood, 95, 2426 2433.
3. Aoudjhane, M., Labopin, M., Gorin, N.C., Shimoni, A., Ruutu, T., Kolb, H.J., Frassoni, F., Boiron, J.M., Yin, J.L., Finke, J., Shouten, H., Blaise, D., Falda, M., Fauser, A.A., Esteve, J., Polge, E., Slavin, S., Niederwieser, D., Nagler, A. Rocha, V. (2005) Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia, 19, 2304 2312.
4. Archbold, J.K., Macdonald, W.A., Miles, J.J., Brennan, R.M., Kjer-Nielsen, L., McCluskey, J., Burrows, S.R. Rossjohn, J. (2006) Alloreactivity between disparate cognate and allogeneic pMHC-I complexes is the result of highly focused, peptide-dependent structural mimicry. Journal of Biological Chemistry, 281, 34324 34332.
5. Aschan, J., Ringden, O., Sundberg, B., Gahrton, G., Ljungman, P. Winiarski, J. (1991) Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy. Bone Marrow Transplantation, 7, 113 119.
6. Aschan, J., Ringden, O., Sundberg, B., Klaesson, S., Ljungman, P. Lonnqvist, B. (1993) Increased risk of relapse in patients with chronic myelogenous leukemia given T-cell depleted marrow compared to methotrexate combined with cyclosporin or monotherapy for the prevention of graft-versus-host disease. European Journal of Haematology, 50, 269 274.
7. Aschan, J., Lonnqvist, B., Ringden, O., Kumlien, G. Gahrton, G. (1996) Graft-versus-myeloma effect. Lancet, 348, 346.
8. Atkinson, K., Horowitz, M.M., Gale, R.P., van Bekkum, D.W., Gluckman, E., Good, R.A., Jacobsen, N., Kolb, H.J., Rimm, A.A. Ringden, O. (1990) Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood, 75, 2459 2464. (Pubitemid 20202328)
9. Aversa, F., Terenzi, A., Tabilio, A., Falzetti, F., Carotti, A., Ballanti, S., Felicini, R., Falcinelli, F., Velardi, A., Ruggeri, L., Aloisi, T., Saab, J.P., Santucci, A., Perruccio, K., Martelli, M.P., Mecucci, C., Reisner, Y. Martelli, M.F. (2005) Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. Journal of Clinical Oncology, 23, 3447 3454.
10. Bacigalupo, A., Van Lint, M.T., Occhini, D., Gualandi, F., Lamparelli, T., Sogno, G., Tedone, E., Frassoni, F., Tong, J. Marmont, A.M. (1991) Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood, 77, 1423 1428.
11. Bacigalupo, A., Lamparelli, T., Bruzzi, P., Guidi, S., Alessandrino, P.E., di Bartolomeo, P., Oneto, R., Bruno, B., Barbanti, M., Sacchi, N., Van Lint, M.T. Bosi, A. (2001) Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood, 98, 2942 2947.
12. Bader, P., Klingebiel, T., Schaudt, A., Theurer-Mainka, U., Handgretinger, R., Lang, P., Niethammer, D. Beck, J.F. (1999) Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children. Leukemia, 13, 2079 2086.
13. Bader, P., Kreyenberg, H., Hoelle, W., Dueckers, G., Handgretinger, R., Lang, P., Kremens, B., Dilloo, D., Sykora, K.W., Schrappe, M., Niemeyer, C., Von Stackelberg, A., Gruhn, B., Henze, G., Greil, J., Niethammer, D., Dietz, K., Beck, J.F. Klingebiel, T. (2004) Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? Journal of Clinical Oncology, 22, 1696 1705.
14. Bahceci, E., Read, E.J., Leitman, S., Childs, R., Dunbar, C., Young, N.S. Barrett, A.J. (2000) CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies. British Journal of Haematology, 108, 408 414.
15. Barker, J.N., Weisdorf, D.J., DeFor, T.E., Blazar, B.R., Miller, J.S. Wagner, J.E. (2003) Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood, 102, 1915 1919.
16. Barker, J.N., Weisdorf, D.J., DeFor, T.E., Blazar, B.R., McGlave, P.B., Miller, J.S., Verfaillie, C.M. Wagner, J.E. (2005) Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood, 105, 1343 1347.
17. Barkholt, L., Danielsson, R., Calissendorff, B., Svensson, L., Malihi, R., Remberger, M., Uzunel, M., Thorne, A. Ringden, O. (2004) Indium-111-labelled donor-lymphocyte infusion by way of hepatic artery and radio-frequency ablation against liver metastases of renal and colon carcinoma after allogeneic hematopoietic stem-cell transplantation. Transplantation, 78, 697 703.
18. Barkholt, L., Bregni, M., Remberger, M., Blaise, D., Peccatori, J., Massenkeil, G., Pedrazzoli, P., Zambelli, A., Bay, J.O., Francois, S., Martino, R., Bengala, C., Brune, M., Lenhoff, S., Porcellini, A., Falda, M., Siena, S., Demirer, T., Niederwieser, D. Ringden, O. (2006) Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Annals of Oncology, 17, 1134 1140. (Pubitemid 43985250)
19. Barnes, D.W., Corp, M.J., Loutit, J.F. Neal, F.E. (1956) Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication. British Medical Journal, 32, 626 627.
20. Baron, F., Petersdorf, E.W., Gooley, T., Sandmaier, B.M., Malkki, M., Chauncey, T.R., Maloney, D.G. Storb, R. (2009) What is the role for donor natural killer cells after nonmyeloablative conditioning? Biology of Blood and Marrow Transplantation, 15, 580 588.
21. Barrett, A.J., Ringden, O., Zhang, M.J., Bashey, A., Cahn, J.Y., Cairo, M.S., Gale, R.P., Gratwohl, A., Locatelli, F., Martino, R., Schultz, K.R. Tiberghien, P. (2000) Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. Blood, 95, 3323 3327.
22. Bay, J.O., Fleury, J., Choufi, B., Tournilhac, O., Vincent, C., Bailly, C., Dauplat, J., Viens, P., Faucher, C. Blaise, D. (2002) Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients. Bone Marrow Transplantation, 30, 95 102.
23. Bensinger, W.I., Weaver, C.H., Appelbaum, F.R., Rowley, S., Demirer, T., Sanders, J., Storb, R. Buckner, C.D. (1995) Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood, 85, 1655 1658.
24. Bensinger, W.I., Clift, R., Martin, P., Appelbaum, F.R., Demirer, T., Gooley, T., Lilleby, K., Rowley, S., Sanders, J., Storb, R. Buckner, C.D. (1996) Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood, 88, 2794 2800. (Pubitemid 26327536)
25. Bensinger, W.I., Martin, P.J., Storer, B., Clift, R., Forman, S.J., Negrin, R., Kashyap, A., Flowers, M.E., Lilleby, K., Chauncey, T.R., Storb, R. Appelbaum, F.R. (2001) Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. New England Journal of Medicine, 344, 175 181.
26. van Besien, K.W., de Lima, M., Giralt, S.A., Moore, D.F., Jr., Khouri, I.F., Rondon, G., Mehra, R., Andersson, B.S., Dyer, C., Cleary, K., Przepiorka, D., Gajewski, J.L. Champlin, R.E. (1997) Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplantation, 19, 977 982.
27. Bishop, M.R., Fowler, D.H., Marchigiani, D., Castro, K., Kasten-Sportes, C., Steinberg, S.M., Gea-Banacloche, J.C., Dean, R., Chow, C.K., Carter, C., Read, E.J., Leitman, S. Gress, R. (2004) Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. Journal of Clinical Oncology, 22, 3886 3892.
28. Bjorkstrand, B.B., Ljungman, P., Svensson, H., Hermans, J., Alegre, A., Apperley, J., Blade, J., Carlson, K., Cavo, M., Ferrant, A., Goldstone, A.H., de Laurenzi, A., Majolino, I., Marcus, R., Prentice, H.G., Remes, K., Samson, D., Sureda, A., Verdonck, L.F., Volin, L. Gahrton, G. (1996) Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood, 88, 4711 4718. (Pubitemid 26419156)
29. Blaise, D., Kuentz, M., Fortanier, C., Bourhis, J.H., Milpied, N., Sutton, L., Jouet, J.P., Attal, M., Bordigoni, P., Cahn, J.Y., Boiron, J.M., Schuller, M.P., Moatti, J.P. Michallet, M. (2000) Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. Journal of Clinical Oncology, 18, 537 546. (Pubitemid 30078535)
30. Blaise, D., Bay, J.O., Faucher, C., Michallet, M., Boiron, J.M., Choufi, B., Cahn, J.Y., Gratecos, N., Sotto, J.J., Francois, S., Fleury, J., Mohty, M., Chabannon, C., Bilger, K., Gravis, G., Viret, F., Braud, A.C., Bardou, V.J., Maraninchi, D. Viens, P. (2004) Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood, 103, 435 441.
31. Bornhauser, M., Schwerdtfeger, R., Martin, H., Frank, K.H., Theuser, C. Ehninger, G. (2004) Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood, 103, 2860 2861.
32. Bortin, M.M., Gale, R.P., Kay, H.E. Rimm, A.A. (1983) Bone marrow transplantation for acute myelogenous leukemia. Factors associated with early mortality. JAMA Journal of the American Medical Association, 249, 1166 1175.
33. Bostrom, L., Ringden, O., Sundberg, B., Ljungman, P., Linde, A. Nilsson, B. (1989) Pretransplant herpes virus serology and chronic graft-versus-host disease. Bone Marrow Transplantation, 4, 547 552.
34. Bostrom, L., Ringden, O., Gratama, J.W., Jacobsen, N., Prentice, H.G., Zwaan, F.E. Nilsson, B. (1990) A role of herpes virus serology for the development of acute graft-versus-host disease. Leukaemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplantation, 5, 321 326.
35. Bostrom, L., Ringden, O., Nilsson, B., Jacobsen, N. Zwaan, F. (1991) Early leukemia, seropositivity for several herpes viruses and chronic graft-versus-host disease are associated with decreased incidence of relapse after allogeneic bone marrow transplantation. Clinical Transplants, 5, 351 358.
36. Bregni, M., Dodero, A., Peccatori, J., Pescarollo, A., Bernardi, M., Sassi, I., Voena, C., Zaniboni, A., Bordignon, C. Corradini, P. (2002) Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood, 99, 4234 4236.
37. Bregni, M., Ueno, N.T. Childs, R. (2006) The second international meeting on allogeneic transplantation in solid tumors. Bone Marrow Transplantation, 38, 527 537.
38. Brickner, A.G., Warren, E.H., Caldwell, J.A., Akatsuka, Y., Golovina, T.N., Zarling, A.L., Shabanowitz, J., Eisenlohr, L.C., Hunt, D.F., Engelhard, V.H. Riddell, S.R. (2001) The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. Journal of Experimental Medicine, 193, 195 206.
39. Brossart, P., Wirths, S., Stuhler, G., Reichardt, V.L., Kanz, L. Brugger, W. (2000) Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood, 96, 3102 3108.
40. Brossart, P., Schneider, A., Dill, P., Schammann, T., Grunebach, F., Wirths, S., Kanz, L., Buhring, H.J. Brugger, W. (2001) The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Research, 61, 6846 6850.
41. Bruno, B., Rotta, M., Patriarca, F., Mordini, N., Allione, B., Carnevale-Schianca, F., Giaccone, L., Sorasio, R., Omede, P., Baldi, I., Bringhen, S., Massaia, M., Aglietta, M., Levis, A., Gallamini, A., Fanin, R., Palumbo, A., Storb, R., Ciccone, G. Boccadoro, M. (2007) A comparison of allografting with autografting for newly diagnosed myeloma. New England Journal of Medicine, 356, 1110 1120. (Pubitemid 46425595)
42. Bruno, B., Rotta, M., Patriarca, F., Mattei, D., Allione, B., Carnevale-Schianca, F., Sorasio, R., Rambaldi, A., Casini, M., Parma, M., Bavaro, P., Onida, F., Busca, A., Castagna, L., Benedetti, E., Iori, A.P., Giaccone, L., Palumbo, A., Corradini, P., Fanin, R., Maloney, D., Storb, R., Baldi, I., Ricardi, U. Boccadoro, M. (2009) Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood, 113, 3375 3382.
43. Bumpus, H.C. (1928) The apparent disappearance of pulmonary metastasis in a case of hypernephroma following nephrectomy. Journal of Urology, 20, 185.
44. Carella, A.M., Beltrami, G., Corsetti, M.T., Scalzulli, P., Carella, A.M., Jr. Musto, P. (2004) A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity. Haematologica, 89, 1534 1536.
45. Carella, A.M., Beltrami, G., Corsetti, M.T., Nati, S., Musto, P., Scalzulli, P., Gonella, R., Ballestrero, A. Patrone, F. (2005) Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet, 366, 318 320.
46. Carlens, S., Aschan, J., Remberger, M., Dilber, M. Ringden, O. (1999) Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia. Bone Marrow Transplantation, 24, 629 635.
47. Carlens, S., Remberger, M., Aschan, J. Ringden, O. (2001) The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse. Biology of Blood and Marrow Transplantation, 7, 31 38.
48. Cavazzana-Calvo, M., Fromont, C., Le Deist, F., Lusardi, M., Coulombel, L., Derocq, J.M., Gerota, I., Griscelli, C. Fischer, A. (1990) Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor B chain-specific immunotoxin. Transplantation, 50, 1 7.
49. Chakraverty, R., Eom, H.S., Sachs, J., Buchli, J., Cotter, P., Hsu, R., Zhao, G. Sykes, M. (2006) Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions. Blood, 108, 2106 2113.
50. Champlin, R.E., Schmitz, N., Horowitz, M.M., Chapuis, B., Chopra, R., Cornelissen, J.J., Gale, R.P., Goldman, J.M., Loberiza, F.R., Jr., Hertenstein, B., Klein, J.P., Montserrat, E., Zhang, M.J., Ringden, O., Tomany, S.C., Rowlings, P.A., Van Hoef, M.E. Gratwohl, A. (2000) Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood, 95, 3702 3709.
51. Chau, I. Cunningham, D. (2009) Treatment in advanced colorectal cancer: what, when and how? British Journal of Cancer, 100, 1704 1719.
52. Childs, R. Srinivasan, R. (2002) Advances in allogeneic stem cell transplantation: directing graft-versus-leukemia at solid tumors. Cancer Journal, 8, 2 11.
53. Childs, R.W. Srinivasan, R. (2004) Allogeneic hematopoietic cell transplantation for solid tumors. In : Thomas' Hematopoietic Cell Transplantation (eds by K.G. Blume, S.J. Forman F.R. Appelbaum pp. 1177 1187. Blackwell Publishing, Ltd., Oxford.
54. Childs, R.W., Clave, E., Tisdale, J., Plante, M., Hensel, N. Barrett, J. (1999) Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. Journal of Clinical Oncology, 17, 2044 2049.
55. Choi, S.J., Lee, J.H., Lee, J.H., Kim, S., Seol, M., Lee, Y.S., Lee, J.S., Kim, W.K., Chi, H.S. Lee, K.H. (2004) Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse. Leukemia, 18, 1789 1797.
56. Choi, C., Witzens, M., Bucur, M., Feuerer, M., Sommerfeldt, N., Trojan, A., Ho, A., Schirrmacher, V., Goldschmidt, H. Beckhove, P. (2005) Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood, 105, 2132 2134.
57. Ciceri, F., Bonini, C., Stanghellini, M.T., Bondanza, A., Traversari, C., Salomoni, M., Turchetto, L., Colombi, S., Bernardi, M., Peccatori, J., Pescarollo, A., Servida, P., Magnani, Z., Perna, S.K., Valtolina, V., Crippa, F., Callegaro, L., Spoldi, E., Crocchiolo, R., Fleischhauer, K., Ponzoni, M., Vago, L., Rossini, S., Santoro, A., Todisco, E., Apperley, J., Olavarria, E., Slavin, S., Weissinger, E.M., Ganser, A., Stadler, M., Yannaki, E., Fassas, A., Anagnostopoulos, A., Bregni, M., Stampino, C.G., Bruzzi, P. Bordignon, C. (2009) Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. The Lancet Oncology, 10, 489 500.
58. Clausen, J., Wolf, D., Petzer, A.L., Gunsilius, E., Schumacher, P., Kircher, B., Gastl, G. Nachbaur, D. (2007) Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clinical and Experimental Immunology, 148, 520 528.
59. Cobbold, M., Khan, N., Pourgheysari, B., Tauro, S., McDonald, D., Osman, H., Assenmacher, M., Billingham, L., Steward, C., Crawley, C., Olavarria, E., Goldman, J., Chakraverty, R., Mahendra, P., Craddock, C. Moss, P.A. (2005) Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. Journal of Experimental Medicine, 202, 379 386.
60. Cohena, Y. Nagler, A. (2003) Hematopoietic stem-cell transplantation using umbilical-cord blood. Leukaemia & Lymphoma, 44, 1287 1299.
61. Collins, R.H., Jr., Shpilberg, O., Drobyski, W.R., Porter, D.L., Giralt, S., Champlin, R., Goodman, S.A., Wolff, S.N., Hu, W., Verfaillie, C., List, A., Dalton, W., Ognoskie, N., Chetrit, A., Antin, J.H. Nemunaitis, J. (1997) Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. Journal of Clinical Oncology, 15, 433 444.
62. Collins, R.H., Jr., Goldstein, S., Giralt, S., Levine, J., Porter, D., Drobyski, W., Barrett, J., Johnson, M., Kirk, A., Horowitz, M. Parker, P. (2000) Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplantation, 26, 511 516.
63. Cooper, M.A., Fehniger, T.A., Fuchs, A., Colonna, M. Caligiuri, M.A. (2004) NK cell and DC interactions. Trends in Immunology, 25, 47 52.
64. Corradini, P., Zallio, F., Mariotti, J., Farina, L., Bregni, M., Valagussa, P., Ciceri, F., Bacigalupo, A., Dodero, A., Lucesole, M., Patriarca, F., Rambaldi, A., Scime, R., Locasciulli, A., Bandini, G., Gianni, A.M., Tarella, C. Olivieri, A. (2005) Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. Journal of Clinical Oncology, 23, 6690 6698.
65. Cutler, C., Giri, S., Jeyapalan, S., Paniagua, D., Viswanathan, A. Antin, J.H. (2001) Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. Journal of Clinical Oncology, 19, 3685 3691.
66. Cutler, C., Kim, H.T., Hochberg, E., Ho, V., Alyea, E., Lee, S.J., Fisher, D.C., Miklos, D., Levin, J., Sonis, S., Soiffer, R.J. Antin, J.H. (2004) Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biology of Blood and Marrow Transplantation, 10, 328 336.
67. Davies, S.M., Ruggieri, L., DeFor, T., Wagner, J.E., Weisdorf, D.J., Miller, J.S., Velardi, A. Blazar, B.R. (2002) Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood, 100, 3825 3827.
68. Dazzi, F., Szydlo, R.M. Goldman, J.M. (1999) Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. Experimental Hematology, 27, 1477 1486.
69. Dazzi, F., Szydlo, R.M., Craddock, C., Cross, N.C., Kaeda, J., Chase, A., Olavarria, E., van Rhee, F., Kanfer, E., Apperley, J.F. Goldman, J.M. (2000a) Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood, 95, 67 71.
70. Dazzi, F., Szydlo, R.M., Cross, N.C., Craddock, C., Kaeda, J., Kanfer, E., Cwynarski, K., Olavarria, E., Yong, A., Apperley, J.F. Goldman, J.M. (2000b) Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood, 96, 2712 2716.
71. Demirer, T., Barkholt, L., Blaise, D., Pedrazzoli, P., Aglietta, M., Carella, A.M., Bay, J.O., Arpaci, F., Rosti, G., Gurman, G., Niederwieser, D. Bregni, M. (2008) Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nature Clinical Practice Oncology, 5, 256 267.
72. Deneberg, S., Lerner, R., Ljungman, P., Ringden, O. Hagglund, H. (2007) Relapse of preB-ALL after rituximab treatment for chronic graft versus host disease: implications for its use? Medical Oncology, 24, 354 356.
73. Dreger, P., Haferlach, T., Eckstein, V., Jacobs, S., Suttorp, M., Loffler, H., Muller-Ruchholtz, W. Schmitz, N. (1994) G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. British Journal of Haematology, 87, 609 613.
74. Dreger, P., Brand, R., Hansz, J., Milligan, D., Corradini, P., Finke, J., Deliliers, G.L., Martino, R., Russell, N., Van Biezen, A., Michallet, M. Niederwieser, D. (2003) Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia, 17, 841 848.
75. Eapen, M., Horowitz, M.M., Klein, J.P., Champlin, R.E., Loberiza, F.R., Jr., Ringden, O. Wagner, J.E. (2004) Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. Journal of Clinical Oncology, 22, 4872 4880.
76. Eapen, M., Rubinstein, P., Zhang, M.J., Stevens, C., Kurtzberg, J., Scaradavou, A., Loberiza, F.R., Champlin, R.E., Klein, J.P., Horowitz, M.M. Wagner, J.E. (2007) Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet, 369, 1947 1954.
77. Espinoza-Delgado, I. Childs, R.W. (2004) Nonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapy. Expert Review of Anticancer Therapy, 4, 865 875.
78. Falkenburg, J.H., Wafelman, A.R., Joosten, P., Smit, W.M., van Bergen, C.A., Bongaerts, R., Lurvink, E., van der Hoorn, M., Kluck, P., Landegent, J.E., Kluin-Nelemans, H.C., Fibbe, W.E. Willemze, R. (1999) Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood, 94, 1201 1208.
79. Farag, S.S., Fehniger, T.A., Ruggeri, L., Velardi, A. Caligiuri, M.A. (2002) Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood, 100, 1935 1947.
80. Fefer, A., Einstein, A.B. Cheever, M.A. (1976) Adoptive chemoimmunotherapy of cancer in animals: a review of results, principles, and problems. Annals of the New York Academy of Sciences, 277, 492 504.
81. Fefer, A., Sullivan, K.M., Weiden, P.L., Buckner, C.D., Schoch, G., Storb, R. Thomas, E.D. (1987) Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than syngeneic marrow transplantation. In : Cellular Immunotherapy of Cancer (eds by R.L. Truitt, R.P. Gale M.M. Bortin pp. 401 408. A R Liss, New York.
82. Ferrara, J.L. Reddy, P. (2006) Pathophysiology of graft-versus-host disease. Seminars in Hematology, 43, 3 10.
83. Flowers, M.E., Leisenring, W., Beach, K., Riddell, S., Radich, J.P., Higano, C.S., Rowley, S.D., Chauncey, T.R., Sanders, J.E., Anasetti, C., Storb, R., Wade, J., Appelbaum, F.R. Martin, P. (2000) Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation. Biology of Blood and Marrow Transplantation, 6, 321 326.
84. Fontaine, P., Roy-Proulx, G., Knafo, L., Baron, C., Roy, D.C. Perreault, C. (2001) Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nature Medicine, 7, 789 794.
85. Gahrton, G., Svensson, H., Cavo, M., Apperly, J., Bacigalupo, A., Bjorkstrand, B., Blade, J., Cornelissen, J., de Laurenzi, A., Facon, T., Ljungman, P., Michallet, M., Niederwieser, D., Powles, R., Reiffers, J., Russell, N.H., Samson, D., Schaefer, U.W., Schattenberg, A., Tura, S., Verdonck, L.F., Vernant, J.P., Willemze, R. Volin, L. (2001) Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. British Journal of Haematology, 113, 209 216.
86. Gale, R.P., Horowitz, M.M., Ash, R.C., Champlin, R.E., Goldman, J.M., Rimm, A.A., Ringden, O., Stone, J.A. Bortin, M.M. (1994) Identical-twin bone marrow transplants for leukemia. Annals of Internal Medicine, 120, 646 652.
87. Gallot, G., Hallet, M.M., Gaschet, J., Moreau, J.F., Vivien, R., Bonneville, M., Milpied, N. Vie, H. (1996) Human HLA-specific T-cell clones with stable expression of a suicide gene: a possible tool to drive and control a graft-versus-host- graft-versus-leukemia reaction? Blood, 88, 1098 1103.
88. Gao, L., Bellantuono, I., Elsasser, A., Marley, S.B., Gordon, M.Y., Goldman, J.M. Stauss, H.J. (2000) Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood, 95, 2198 2203.
89. Garban, F., Attal, M., Michallet, M., Hulin, C., Bourhis, J.H., Yakoub-Agha, I., Lamy, T., Marit, G., Maloisel, F., Berthou, C., Dib, M., Caillot, D., Deprijck, B., Ketterer, N., Harousseau, J.L., Sotto, J.J. Moreau, P. (2006) Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood, 107, 3474 3480.
90. Gattinoni, L., Finkelstein, S.E., Klebanoff, C.A., Antony, P.A., Palmer, D.C., Spiess, P.J., Hwang, L.N., Yu, Z., Wrzesinski, C., Heimann, D.M., Surh, C.D., Rosenberg, S.A. Restifo, N.P. (2005) Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. Journal of Experimental Medicine, 202, 907 912.
91. Giebel, S., Locatelli, F., Lamparelli, T., Velardi, A., Davies, S., Frumento, G., Maccario, R., Bonetti, F., Wojnar, J., Martinetti, M., Frassoni, F., Giorgiani, G., Bacigalupo, A. Holowiecki, J. (2003) Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood, 102, 814 819.
92. Giralt, S., Estey, E., Albitar, M., van Besien, K., Rondon, G., Anderlini, P., O'Brien, S., Khouri, I., Gajewski, J., Mehra, R., Claxton, D., Andersson, B., Beran, M., Przepiorka, D., Koller, C., Kornblau, S., Korbling, M., Keating, M., Kantarjian, H. Champlin, R. (1997) Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood, 89, 4531 4536.
93. Giralt, S., Thall, P.F., Khouri, I., Wang, X., Braunschweig, I., Ippolitti, C., Claxton, D., Donato, M., Bruton, J., Cohen, A., Davis, M., Andersson, B.S., Anderlini, P., Gajewski, J., Kornblau, S., Andreeff, M., Przepiorka, D., Ueno, N.T., Molldrem, J. Champlin, R. (2001) Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood, 97, 631 637.
94. Glass, B., Uharek, L., Zeis, M., Dreger, P., Loffler, H., Steinmann, J. Schmitz, N. (1997) Allogeneic peripheral blood progenitor cell transplantation in a murine model: evidence for an improved graft-versus-leukemia effect. Blood, 90, 1694 1700.
95. Goldman, J.M., Gale, R.P., Horowitz, M.M., Biggs, J.C., Champlin, R.E., Gluckman, E., Hoffmann, R.G., Jacobsen, S.J., Marmont, A.M., McGlave, P.B., Messner, H.A., Rimm, A.A., Rozman, C., Speck, B., Tura, S., Weiner, R.S. Bortin, M.M. (1988) Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Annals of Internal Medicine, 108, 806 814. (Pubitemid 18173559)
96. Goulmy, E. (2006) Minor histocompatibility antigens: from transplantation problems to therapy of cancer. Human Immunology, 67, 433 438.
97. Goulmy, E., Termijtelen, A., Bradley, B.A. van Rood, J.J. (1976) Alloimmunity to human H-Y. Lancet, 2, 1206.
98. Gratwohl, A., Hermans, J., Apperley, J., Arcese, W., Bacigalupo, A., Bandini, G., di Bartolomeo, P., Boogaerts, M., Bosi, A. Carreras, E. (1995) Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Blood, 86, 813 818.
99. Gribben, J.G. (2008) Stem cell transplantation in chronic lymphocytic leukemia. Biology of Blood and Marrow Transplantation, 15, 53 58.
100. Gustafsson, A., Levitsky, V., Zou, J.Z., Frisan, T., Dalianis, T., Ljungman, P., Ringden, O., Winiarski, J., Ernberg, I. Masucci, M.G. (2000) Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood, 95, 807 814.
101. Hanley, P.J., Cruz, C.R., Savoldo, B., Leen, A.M., Stanojevic, M., Khalil, M., Decker, W., Molldrem, J.J., Liu, H., Gee, A.P., Rooney, C.M., Heslop, H.E., Dotti, G., Brenner, M.K., Shpall, E.J. Bollard, C.M. (2009) Functionally active virus-specific T-cells that target CMV, adenovirus and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood, 114, 1958 1967.
102. Haque, T., Wilkie, G.M., Taylor, C., Amlot, P.L., Murad, P., Iley, A., Dombagoda, D., Britton, K.M., Swerdlow, A.J. Crawford, D.H. (2002) Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet, 360, 436 442.
103. Haque, T., Wilkie, G.M., Jones, M.M., Higgins, C.D., Urquhart, G., Wingate, P., Burns, D., McAulay, K., Turner, M., Bellamy, C., Amlot, P.L., Kelly, D., MacGilchrist, A., Gandhi, M.K., Swerdlow, A.J. Crawford, D.H. (2007) Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood, 110, 1123 1131.
104. Hauch, M., Gazzola, M.V., Small, T., Bordignon, C., Barnett, L., Cunningham, I., Castro-Malaspinia, H., O'Reilly, R.J. Keever, C.A. (1990) Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood, 75, 2250 2262.
105. Heldal, D., Tjonnfjord, G., Brinch, L., Albrechtsen, D., Egeland, T., Steen, R., Solheim, B.G. Evensen, S.A. (2000) A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplantation, 25, 1129 1136.
106. Hentschke, P., Barkholt, L., Uzunel, M., Mattsson, J., Wersall, P., Pisa, P., Martola, J., Albiin, N., Wernerson, A., Soderberg, M., Remberger, M., Thorne, A. Ringden, O. (2003) Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplantation, 31, 253 261.
107. Heslop, H.E., Brenner, M.K. Rooney, C.M. (1994) Donor T cells to treat EBV-associated lymphoma. New England Journal of Medicine, 331, 679 680.
108. Hishizawa, M., Imada, K., Sakai, T., Ueda, M. Uchiyama, T. (2005) Identification of APOBEC3B as a potential target for the graft-versus-lymphoma effect by SEREX in a patient with mantle cell lymphoma. British Journal of Haematology, 130, 418 421.
109. Hishizawa, M., Imada, K., Sakai, T., Nishikori, M., Arima, N., Tsudo, M., Ishikawa, T. Uchiyama, T. (2006) Antibody responses associated with the graft-versus-leukemia effect in adult T-cell leukemia. International Journal of Hematology, 83, 351 355.
110. Horowitz, M.M., Gale, R.P., Sondel, P.M., Goldman, J.M., Kersey, J., Kolb, H.J., Rimm, A.A., Ringden, O., Rozman, C. Speck, B. (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood, 75, 555 562. (Pubitemid 20069191)
111. Hsieh, M.H. Korngold, R. (2000) Differential use of FasL- and perforin-mediated cytolytic mechanisms by T-cell subsets involved in graft-versus-myeloid leukemia responses. Blood, 96, 1047 1055.
112. Hsu, K.C., Keever-Taylor, C.A., Wilton, A., Pinto, C., Heller, G., Arkun, K., O'Reilly, R.J., Horowitz, M.M. Dupont, B. (2005) Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood, 105, 4878 4884.
113. Hsu, K.C., Gooley, T., Malkki, M., Pinto-Agnello, C., Dupont, B., Bignon, J.D., Bornhauser, M., Christiansen, F., Gratwohl, A., Morishima, Y., Oudshoorn, M., Ringden, O., van Rood, J.J. Petersdorf, E. (2006) KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biology of Blood and Marrow Transplantation, 12, 828 836.
114. Igarashi, T., Wynberg, J., Srinivasan, R., Becknell, B., McCoy, J.P., Takahashi, Y., Suffredini, D.A., Linehan, W.M., Caligiuri, M.A. Childs, R.W. (2004) Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood, 104, 170 177.
115. Jacobsen, N., Keiding, N., Lönnqvist, B., Rajantie, J., Volin, L., Jacobsen, N., Ryder, L., Ringdén, O., Gahrton, G., Siimes, M., Ruutu, T., Toivvanen, A., Nikoskelainen, J. Andersen, H. K. From the Nordic Bone Marrow Transplantation Group and the Tissue Typing Laboratory, Rigshospitalet, Copenhagen, Denmark (1987) Graft-versus-leukaemia activity associated with cytomegalovirus antibody positive bone marrow donors in acute myeloid leukaemia. Lancet, 329, 456 457.
116. Jiang, Y.Z., Kanfer, E.J., Macdonald, D., Cullis, J.O., Goldman, J.M. Barrett, A.J. (1991) Graft-versus-leukaemia following allogeneic bone marrow transplantation: emergence of cytotoxic T lymphocytes reacting to host leukaemia cells. Bone Marrow Transplantation, 8, 253 258.
117. Jones, R.J., Ambinder, R.F., Piantadosi, S. Santos, G.W. (1991) Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood, 77, 649 653.
118. Kanda, Y., Komatsu, Y., Akahane, M., Kojima, S., Asano-Mori, Y., Tada, M., Oshima, K., Isayama, H., Ogawa, S., Motokura, T., Chiba, S., Ohtomo, K., Omata, M. Hirai, H. (2005) Graft-versus-tumor effect against advanced pancreatic cancer after allogeneic reduced-intensity stem cell transplantation. Transplantation, 79, 821 827.
119. Kanda, Y., Omuro, Y., Baba, E., Oshima, K., Nagafuji, K., Heike, Y., Takaue, Y., Sasaki, T., Sakamaki, H. Harada, M. (2008) Allo-SCT using reduced-intensity conditioning against advanced pancreatic cancer: a Japanese survey. Bone Marrow Transplantation, 42, 99 103.
120. Kapp, M., Stevanovic, S., Fick, K., Tan, S.M., Loeffler, J., Opitz, A., Tonn, T., Stuhler, G., Einsele, H. Grigoleit, G.U. (2009) CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT. Bone Marrow Transplantation, 43, 399 410.
121. Kapur, R., Ebeling, S. Hagenbeek, A. (2008) B-cell involvement in chronic graft-versus-host disease. Haematologica, 93, 1702 1711.
122. Karlsson, H., Brewin, J., Kinnon, C., Veys, P. Amrolia, P.J. (2007) Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens. Journal of Immunotherapy, 30, 544 556.
123. Kawase, T., Matsuo, K., Kashiwase, K., Inoko, H., Saji, H., Ogawa, S., Kato, S., Sasazuki, T., Kodera, Y. Morishima, Y. (2009) HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism. Blood, 113, 2851 2858.
124. Khouri, I.F., Lee, M.S., Saliba, R.M., Andersson, B., Anderlini, P., Couriel, D., Hosing, C., Giralt, S., Korbling, M., McMannis, J., Keating, M.J. Champlin, R.E. (2004) Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Experimental Hematology, 32, 28 35.
125. Kolb, H.J., Mittermuller, J., Clemm, C., Holler, E., Ledderose, G., Brehm, G., Heim, M. Wilmanns, W. (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood, 76, 2462 2465.
126. Kolb, H.J., Schattenberg, A., Goldman, J.M., Hertenstein, B., Jacobsen, N., Arcese, W., Ljungman, P., Ferrant, A., Verdonck, L., Niederwieser, D., van Rhee, F., Mittermueller, J., de Witte, T., Holler, E. Ansari, H. (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood, 86, 2041 2050.
127. Kronig, H., Hofer, K., Conrad, H., Guilaume, P., Muller, J., Schiemann, M., Lennerz, V., Cosma, A., Peschel, C., Busch, D.H., Romero, P. Bernhard, H. (2009) Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity. International Journal of Cancer, 125, 649 655.
128. Lang, P., Barbin, K., Feuchtinger, T., Greil, J., Peipp, M., Zunino, S.J., Pfeiffer, M., Handgretinger, R., Niethammer, D. Fey, G.H. (2004) Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allografts. Blood, 103, 3982 3985.
129. Le Blanc, R., Montminy-Metivier, S., Belanger, R., Busque, L., Fish, D., Roy, D.C., Kassis, J., Boileau, J., Lavallee, R., Belanger, D., Letendre, F., Hebert, J., Sauvageau, G., Perreault, C. Roy, J. (2001) Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect. Bone Marrow Transplantation, 28, 841 848.
130. Leen, A.M., Myers, G.D., Sili, U., Huls, M.H., Weiss, H., Leung, K.S., Carrum, G., Krance, R.A., Chang, C.C., Molldrem, J.J., Gee, A.P., Brenner, M.K., Heslop, H.E., Rooney, C.M. Bollard, C.M. (2006) Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nature Medicine, 12, 1160 1166.
131. Levine, J.E., Braun, T., Penza, S.L., Beatty, P., Cornetta, K., Martino, R., Drobyski, W.R., Barrett, A.J., Porter, D.L., Giralt, S., Leis, J., Holmes, H.E., Johnson, M., Horowitz, M. Collins, R.H., Jr. (2002) Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. Journal of Clinical Oncology, 20, 405 412.
132. Ljunggren, H.G. Karre, K. (1990) In search of the 'missing self': MHC molecules and NK cell recognition. Immunology Today, 11, 237 244.
133. Lokhorst, H.M., Schattenberg, A., Cornelissen, J.J., van Oers, M.H., Fibbe, W., Russell, I., Donk, N.W. Verdonck, L.F. (2000) Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. Journal of Clinical Oncology, 18, 3031 3037.
134. Lonnqvist, B., Ringden, O., Ljungman, P., Wahren, B. Gahrton, G. (1986) Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection. British Journal of Haematology, 63, 671 679.
135. Luznik, L., Slansky, J.E., Jalla, S., Borrello, I., Levitsky, H.I., Pardoll, D.M. Fuchs, E.J. (2003) Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood, 101, 1645 1652.
136. Mackinnon, S., Papadopoulos, E.B., Carabasi, M.H., Reich, L., Collins, N.H., Boulad, F., Castro-Malaspina, H., Childs, B.H., Gillio, A.P. Kernan, N.A. (1995) Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood, 86, 1261 1268.
137. Mailander, V., Scheibenbogen, C., Thiel, E., Letsch, A., Blau, I.W. Keilholz, U. (2004) Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia, 18, 165 166.
138. Malladi, R.K., Peniket, A.J., Norton, A.E., Campbell, A.J., Collins, G.P., Samol, J., Eagleton, H., Miller, E., Morgenstern, G., Jones, J., Keen-Mcguire, A., Barnardo, M. Littlewood, T.J. (2004) Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies. European Journal of Haematology, 73, 85 92.
139. Maloney, D.G., Molina, A.J., Sahebi, F., Stockerl-Goldstein, K.E., Sandmaier, B.M., Bensinger, W., Storer, B., Hegenbart, U., Somlo, G., Chauncey, T., Bruno, B., Appelbaum, F.R., Blume, K.G., Forman, S.J., McSweeney, P. Storb, R. (2003) Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood, 102, 3447 3454.
140. Maris, M.B., Sandmaier, B.M., Storer, B.E., Chauncey, T., Stuart, M.J., Maziarz, R.T., Agura, E., Langston, A.A., Pulsipher, M., Storb, R. Maloney, D.G. (2004) Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood, 104, 3535 3542.
141. Marks, D.I., Lush, R., Cavenagh, J., Milligan, D.W., Schey, S., Parker, A., Clark, F.J., Hunt, L., Yin, J., Fuller, S., Vandenberghe, E., Marsh, J., Littlewood, T., Smith, G.M., Culligan, D., Hunter, A., Chopra, R., Davies, A., Towlson, K. Williams, C.D. (2002) The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood, 100, 3108 3114.
142. Marmont, A.M., Horowitz, M.M., Gale, R.P., Sobocinski, K., Ash, R.C., van Bekkum, D.W., Champlin, R.E., Dicke, K.A., Goldman, J.M. Good, R.A. (1991) T-cell depletion of HLA-identical transplants in leukemia. Blood, 78, 2120 2130.
143. Mattsson, J., Uzunel, M., Tammik, L., Aschan, J. Ringden, O. (2001) Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. Leukemia, 15, 1976 1985.
144. Mattsson, J., Ringden, O. Storb, R. (2008) Graft failure after allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation, 14, 165 170.
145. Mavroudis, D.A., Jiang, Y.Z., Hensel, N., Lewalle, P., Couriel, D., Kreitman, R.J., Pastan, I. Barrett, A.J. (1996) Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation. Bone Marrow Transplantation, 17, 793 799.
146. McSweeney, P.A. Storb, R. (1999) Mixed chimerism: preclinical studies and clinical applications. Biology of Blood and Marrow Transplantation, 5, 192 203.
147. Miller, J.S., Cooley, S., Parham, P., Farag, S.S., Verneris, M.R., McQueen, K.L., Guethlein, L.A., Trachtenberg, E.A., Haagenson, M., Horowitz, M.M., Klein, J.P. Weisdorf, D.J. (2007) Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood, 109, 5058 5061.
148. Morecki, S., Moshel, Y., Gelfend, Y., Pugatsch, T. Slavin, S. (1997) Induction of graft vs. tumor effect in a murine model of mammary adenocarcinoma. International Journal of Cancer, 71, 59 63.
149. Mutis, T., Verdijk, R., Schrama, E., Esendam, B., Brand, A. Goulmy, E. (1999) Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood, 93, 2336 2341.
150. Nash, R.A., Pineiro, L.A., Storb, R., Deeg, H.J., Fitzsimmons, W.E., Furlong, T., Hansen, J.A., Gooley, T., Maher, R.M., Martin, P., McSweeney, P.A., Sullivan, K.M., Anasetti, C. Fay, J.W. (1996) FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood, 88, 3634 3641. (Pubitemid 26365603)
151. Nordlander, A., Mattsson, J., Ringden, O., Leblanc, K., Gustafsson, B., Ljungman, P., Svenberg, P., Svennilson, J. Remberger, M. (2004) Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. Biology of Blood and Marrow Transplantation, 10, 195 203.
152. Odom, L.F., August, C.S., Githens, J.H., Humbert, J.R., Morse, H., Peakman, D., Sharma, B., Rusnak, S.L. Johnson, F.B. (1978) Remission of relapsed leukaemia during a graft-versus-host reaction. A "graft-versus-leukaemia reaction" in man? Lancet, 2, 537 540.
153. Ohminami, H., Yasukawa, M. Fujita, S. (2000) HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood, 95, 286 293.
154. Oka, Y., Elisseeva, O.A., Tsuboi, A., Ogawa, H., Tamaki, H., Li, H., Oji, Y., Kim, E.H., Soma, T., Asada, M., Ueda, K., Maruya, E., Saji, H., Kishimoto, T., Udaka, K. Sugiyama, H. (2000) Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics, 51, 99 107. (Pubitemid 30150969)
155. Omuro, Y., Matsumoto, G., Sasaki, T., Tanaka, Y., Maeda, Y., Sakamaki, H., Hiruma, K., Tsuruta, K. Takahashi, T. (2003) Regression of an unresectable pancreatic tumor following nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. Bone Marrow Transplantation, 31, 943 945.
156. Or, R., Shapira, M.Y., Resnick, I., Amar, A., Ackerstein, A., Samuel, S., Aker, M., Naparstek, E., Nagler, A. Slavin, S. (2003) Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood, 101, 441 445.
157. Paulin, T. (1992) Importance of bone marrow cell dose in bone marrow transplantation. Clinical Transplantation, 6, 48 54.
158. Pedrazzoli, P., Da Prada, G.A., Giorgiani, G., Schiavo, R., Zambelli, A., Giraldi, E., Landonio, G., Locatelli, F., Siena, S. Della Cuna, G.R. (2002) Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer, 94, 2409 2415.
159. Perez-Simon, J.A., Caballero, D., Diez-Campelo, M., Lopez-Perez, R., Mateos, G., Canizo, C., Vazquez, L., Vidriales, B., Mateos, M.V., Gonzalez, M. San Miguel, J.F. (2002) Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia, 16, 1423 1431.
160. Pirker, R., Pereira, J.R., Szczesna, A., von Pawel, J., Krzakowski, M., Ramlau, R., Vynnychenko, I., Park, K., Yu, C.T., Ganul, V., Roh, J.K., Bajetta, E., O'Byrne, K., de Marinis, F., Eberhardt, W., Goddemeier, T., Emig, M. Gatzemeier, U. (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet, 373, 1525 1531.
161. Quintarelli, C., Dotti, G., De Angelis, B., Hoyos, V., Mims, M., Luciano, L., Heslop, H.E., Rooney, C.M., Pane, F. Savoldo, B. (2008) Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood, 112, 1876 1885.
162. Raiola, A.M., Van Lint, M.T., Valbonesi, M., Lamparelli, T., Gualandi, F., Occhini, D., Bregante, S., di Grazia, C., Dominietto, A., Soracco, M., Romagnani, C., Vassallo, F., Casini, M., Bruno, B., Frassoni, F. Bacigalupo, A. (2003) Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplantation, 31, 687 693.
163. Remberger, M., Storer, B., Ringden, O. Anasetti, C. (2002) Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplantation, 29, 391 397.
164. Remberger, M., Beelen, D.W., Fauser, A., Basara, N., Basu, O. Ringden, O. (2005) Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood, 105, 548 551.
165. Rezvani, K. Barrett, A.J. (2008) Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation. Best Practice & Research Clinical Haematology, 21, 437 453.
166. Rezvani, K., Grube, M., Brenchley, J.M., Sconocchia, G., Fujiwara, H., Price, D.A., Gostick, E., Yamada, K., Melenhorst, J., Childs, R., Hensel, N., Douek, D.C. Barrett, A.J. (2003) Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood, 102, 2892 2900.
167. Rezvani, K., Brenchley, J.M., Price, D.A., Kilical, Y., Gostick, E., Sewell, A.K., Li, J., Mielke, S., Douek, D.C. Barrett, A.J. (2005) T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clinical Cancer Research, 11, 8799 8807.
168. Rezvani, K., Yong, A.S., Mielke, S., Savani, B.N., Musse, L., Superata, J., Jafarpour, B., Boss, C. Barrett, A.J. (2008) Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood, 111, 236 242.
169. Riddell, S.R., Watanabe, K.S., Goodrich, J.M., Li, C.R., Agha, M.E. Greenberg, P.D. (1992) Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science, 257, 238 241.
170. Ringden, O. Horowitz, M.M. (1989) Graft-versus-leukemia reactions in humans. The Advisory Committee of the International Bone Marrow Transplant Registry. Transplantation Proceedings, 21, 2989 2992.
171. Ringden, O. Nilsson, B. (1985) Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy. Transplantation, 40, 39 44.
172. Ringden, O., Paulin, T., Lonnqvist, B. Nilsson, B. (1985) An analysis of factors predisposing to chronic graft-versus-host disease. Experimental Hematology, 13, 1062 1067.
173. Ringden, O., Zwaan, F., Hermans, J. Gratwohl, A. (1987) European experience of bone marrow transplantation for leukemia. Transplantation Proceedings, 19, 2600 2604.
174. Ringden, O., Pihlstedt, P., Markling, L., Aschan, J., Baryd, I., Ljungman, P., Lonnqvist, B., Tollemar, J., Janossy, G. Sundberg, B. (1991) Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplantation, 7, 221 226.
175. Ringden, O., Horowitz, M.M., Sondel, P., Gale, R.P., Biggs, J.C., Champlin, R.E., Deeg, H.J., Dicke, K., Masaoka, T. Powles, R.L. (1993) Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood, 81, 1094 1101.
176. Ringden, O., Remberger, M., Persson, U., Ljungman, P., Aldener, A., Andstrom, E., Aschan, J., Bolme, P., Dahllof, G., Dalianis, T., Gahrton, G., Hagglund, H., Lonnqvist, B., Olerup, O., Shanwell, A., Sparrelid, E., Winiarski, J., Moller, E. Oberg, M. (1995) Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplantation, 15, 619 625.
177. Ringden, O., Labopin, M., Gluckman, E., Reiffers, J., Vernant, J.P., Jouet, J.P., Harrousseau, J.L., Fiere, D., Bacigalupo, A., Frassoni, F. Gorin, N.C. (1996a) Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 18, 921 929.
178. Ringden, O., Hermans, J., Labopin, M., Apperley, J., Gorin, N.C. Gratwohl, A. (1996b) The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). Leukaemia & Lymphoma, 24, 71 79.
179. Ringden, O., Labopin, M., Gorin, N.C., Schmitz, N., Schaefer, U.W., Prentice, H.G., Bergmann, L., Jouet, J.P., Mandelli, F., Blaise, D., Fouillard, L. Frassoni, F. (2000) Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia? British Journal of Haematology, 111, 1130 1137. (Pubitemid 32104929)
180. Ringden, O., Labopin, M., Bacigalupo, A., Arcese, W., Schaefer, U.W., Willemze, R., Koc, H., Bunjes, D., Gluckman, E., Rocha, V., Schattenberg, A. Frassoni, F. (2002) Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. Journal of Clinical Oncology, 20, 4655 4664. (Pubitemid 36025282)
181. Ringden, O., Barrett, A.J., Zhang, M.J., Loberiza, F.R., Bolwell, B.J., Cairo, M.S., Gale, R.P., Hale, G.A., Litzow, M.R., Martino, R., Russell, J.A., Tiberghien, P., Urbano-Ispizua, A. Horowitz, M.M. (2003) Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. British Journal of Haematology, 121, 874 885.
182. Ringden, O., Pavletic, S.Z., Anasetti, C., Barrett, A.J., Wang, T., Wang, D., Antin, J.H., Di Bartolomeo, P., Bolwell, B.J., Bredeson, C., Cairo, M.S., Gale, R.P., Gupta, V., Hahn, T., Hale, G.A., Halter, J., Jagasia, M., Litzow, M.R., Locatelli, F., Marks, D.I., McCarthy, P.L., Cowan, M.J., Petersdorf, E.W., Russell, J.A., Schiller, G.J., Schouten, H., Spellman, S., Verdonck, L.F., Wingard, J.R., Horowitz, M.M. Arora, M. (2009) The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood, 113, 3110 3118.
183. Rocha, V. Gluckman, E. (2006) Clinical use of umbilical cord blood hematopoietic stem cells. Biology of Blood and Marrow Transplantation, 12, 34 41.
184. Rocha, V., Cornish, J., Sievers, E.L., Filipovich, A., Locatelli, F., Peters, C., Remberger, M., Michel, G., Arcese, W., Dallorso, S., Tiedemann, K., Busca, A., Chan, K.W., Kato, S., Ortega, J., Vowels, M., Zander, A., Souillet, G., Oakill, A., Woolfrey, A., Pay, A.L., Green, A., Garnier, F., Ionescu, I., Wernet, P., Sirchia, G., Rubinstein, P., Chevret, S. Gluckman, E. (2001) Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood, 97, 2962 2971.
185. Rocha, V., Labopin, M., Gluckman, E., Powles, R., Arcese, W., Bacigalupo, A., Reiffers, J., Iriondo, A., Ringden, O., Ruutu, T. Frassoni, F. (2002) Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukemia in first complete remission: results of a European survey. Journal of Clinical Oncology, 20, 4324 4330.
186. Rooney, C.M., Smith, C.A., Ng, C.Y., Loftin, S.K., Sixbey, J.W., Gan, Y., Srivastava, D.K., Bowman, L.C., Krance, R.A., Brenner, M.K. Heslop, H.E. (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood, 92, 1549 1555.
187. Rosenberg, S.A., Yang, J.C., Topalian, S.L., Schwartzentruber, D.J., Weber, J.S., Parkinson, D.R., Seipp, C.A., Einhorn, J.H. White, D.E. (1994a) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. Journal of the American Medical Association, 271, 907 913.
188. Rosenberg, S.A., Yannelli, J.R., Yang, J.C., Topalian, S.L., Schwartzentruber, D.J., Weber, J.S., Parkinson, D.R., Seipp, C.A., Einhorn, J.H. White, D.E. (1994b) Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. Journal of the National Cancer Institute, 86, 1159 1166.
189. Rosenberg, S.A., Restifo, N.P., Yang, J.C., Morgan, R.A. Dudley, M.E. (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nature Reviews Cancer, 8, 299 308.
190. Rossig, C., Bollard, C.M., Nuchtern, J.G., Rooney, C.M. Brenner, M.K. (2002) Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood, 99, 2009 2016.
191. Ruggeri, L., Capanni, M., Casucci, M., Volpi, I., Tosti, A., Perruccio, K., Urbani, E., Negrin, R.S., Martelli, M.F. Velardi, A. (1999) Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood, 94, 333 339.
192. Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W.D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., Martelli, M.F. Velardi, A. (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science, 295, 2097 2100.
193. Savoldo, B., Rooney, C.M., Di Stasi, A., Abken, H., Hombach, A., Foster, A.E., Zhang, L., Heslop, H.E., Brenner, M.K. Dotti, G. (2007) Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood, 110, 2620 2630.
194. Schaffer, M., Malmberg, K.J., Ringden, O., Ljunggren, H.G. Remberger, M. (2004) Increased infection-related mortality in KIR-ligand-mismatched unrelated allogeneic hematopoietic stem-cell transplantation. Transplantation, 78, 1081 1085.
195. Schmaltz, C., Alpdogan, O., Muriglan, S.J., Kappel, B.J., Rotolo, J.A., Ricchetti, E.T., Greenberg, A.S., Willis, L.M., Murphy, G.F., Crawford, J.M. van den Brink, M.R. (2003) Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood, 101, 2440 2445.
196. Schmid, C., Labopin, M., Nagler, A., Bornhauser, M., Finke, J., Fassas, A., Volin, L., Gurman, G., Maertens, J., Bordigoni, P., Holler, E., Ehninger, G., Polge, E., Gorin, N.C., Kolb, H.J. Rocha, V. (2007) Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. Journal of Clinical Oncology, 25, 4938 4945.
197. Schmitz, N., Beksac, M., Hasenclever, D., Bacigalupo, A., Ruutu, T., Nagler, A., Gluckman, E., Russell, N., Apperley, J.F., Gorin, N.C., Szer, J., Bradstock, K., Buzyn, A., Clark, P., Borkett, K. Gratwohl, A. (2002) Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood, 100, 761 767.
198. Shiobara, S., Nakao, S., Ueda, M., Yamazaki, H., Takahashi, S., Asano, S., Yabe, H., Kato, S., Imoto, S., Maruta, A., Yoshida, T., Gondo, H., Morishima, Y. Kodera, Y. (2000) Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Bone Marrow Transplantation, 26, 769 774.
199. Sierra, J., Storer, B., Hansen, J.A., Bjerke, J.W., Martin, P.J., Petersdorf, E.W., Appelbaum, F.R., Bryant, E., Chauncey, T.R., Sale, G., Sanders, J.E., Storb, R., Sullivan, K.M. Anasetti, C. (1997) Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood, 89, 4226 4235.
200. Slavin, S., Naparstek, E., Nagler, A., Ackerstein, A., Samuel, S., Kapelushnik, J., Brautbar, C. Or, R. (1996) Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood, 87, 2195 2204.
201. Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., Amar, A., Brautbar, C., Ben-Tal, O., Eldor, A. Or, R. (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood, 91, 756 763.
202. Soderdahl, G., Barkholt, L., Hentschke, P., Mattsson, J., Uzunel, M., Ericzon, B.G. Ringden, O. (2003) Liver transplantation followed by adjuvant nonmyeloablative hemopoietic stem cell transplantation for advanced primary liver cancer in humans. Transplantation, 75, 1061 1066.
203. Solomon, S.R., Mielke, S., Savani, B.N., Montero, A., Wisch, L., Childs, R., Hensel, N., Schindler, J., Ghetie, V., Leitman, S.F., Mai, T., Carter, C.S., Kurlander, R., Read, E.J., Vitetta, E.S. Barrett, A.J. (2005) Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood, 106, 1123 1129.
204. Storb, R., Prentice, R.L. Thomas, E.D. (1977) Marrow transplantation for treatment of aplastic anemia. An analysis of factors associated with graft rejection. New England Journal of Medicine, 296, 61 66.
205. Storb, R., Prentice, R.L., Sullivan, K.M., Shulman, H.M., Deeg, H.J., Doney, K.C., Buckner, C.D., Clift, R.A., Witherspoon, R.P., Appelbaum, F.A., Sanders, J.E., Stewart, P.S. Thomas, E.D. (1983) Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Annals of Internal Medicine, 98, 461 466.
206. Storb, R., Deeg, H.J., Pepe, M., Appelbaum, F., Anasetti, C., Beatty, P., Bensinger, W., Berenson, R., Buckner, C.D. Clift, R. (1989) Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood, 73, 1729 1734. (Pubitemid 19131924)
207. Storb, R.F., Champlin, R., Riddell, S.R., Murata, M., Bryant, S. Warren, E.H. (2001) Non-myeloablative transplants for malignant disease. Hematology American Society of Hematology Education Program, 2001, 375 391.
208. Storek, J., Gooley, T., Siadak, M., Bensinger, W.I., Maloney, D.G., Chauncey, T.R., Flowers, M., Sullivan, K.M., Witherspoon, R.P., Rowley, S.D., Hansen, J.A., Storb, R. Appelbaum, F.R. (1997) Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood, 90, 4705 4709.
209. Sullivan, K.M., Weiden, P.L., Storb, R., Witherspoon, R.P., Fefer, A., Fisher, L., Buckner, C.D., Anasetti, C., Appelbaum, F.R. Badger, C. (1989) Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood, 73, 1720 1728. (Pubitemid 19133213)
210. Svahn, B.M., Remberger, M., Myrback, K.E., Holmberg, K., Eriksson, B., Hentschke, P., Aschan, J., Barkholt, L. Ringden, O. (2002) Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. Blood, 100, 4317 4324.
211. Svahn, B.M., Ringden, O. Remberger, M. (2005) Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplantation, 36, 511 516.
212. Takahashi, T., Omuro, Y., Matsumoto, G., Sakamaki, H., Maeda, Y., Hiruma, K., Tsuruta, K. Sasaki, T. (2004) Nonmyeloablative allogeneic stem cell transplantation for patients with unresectable pancreatic cancer. Pancreas, 28, e65 e69.
213. Takahashi, Y., Harashima, N., Kajigaya, S., Yokoyama, H., Cherkasova, E., McCoy, J.P., Hanada, K., Mena, O., Kurlander, R., Tawab, A., Srinivasan, R., Lundqvist, A., Malinzak, E., Geller, N., Lerman, M.I. Childs, R.W. (2008) Regression of human kidney cancer following allogeneic stem cell transplantation
214. Tauro, S., Craddock, C., Peggs, K., Begum, G., Mahendra, P., Cook, G., Marsh, J., Milligan, D., Goldstone, A., Hunter, A., Khwaja, A., Chopra, R., Littlewood, T., Peniket, A., Parker, A., Jackson, G., Hale, G., Cook, M., Russell, N. Mackinnon, S. (2005) Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. Journal of Clinical Oncology, 23, 9387 9393.
215. Thomas, E.D., Lochte, H.L., Jr., Lu, W.C. Ferrebee, J.W. (1957) Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. New England Journal of Medicine, 257, 491 496.
216. Thompson Coon, J.S., Liu, Z., Hoyle, M., Rogers, G., Green, C., Moxham, T., Welch, K. Stein, K. (2009) Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. British Journal of Cancer, 101, 238 243.
217. Tiberghien, P., Reynolds, C.W., Keller, J., Spence, S., Deschaseaux, M., Certoux, J.M., Contassot, E., Murphy, W.J., Lyons, R. Chiang, Y. (1994) Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? Blood, 84, 1333 1341.
218. Tollemar, J., Ringden, O., Bostrom, L., Nilsson, B. Sundberg, B. (1989) Variables predicting deep fungal infections in bone marrow transplant recipients. Bone Marrow Transplantation, 4, 635 641.
219. Tricot, G., Vesole, D.H., Jagannath, S., Hilton, J., Munshi, N. Barlogie, B. (1996) Graft-versus-myeloma effect: proof of principle. Blood, 87, 1196 1198.
220. Truitt, R.L. Atasoylu, A.A. (1991) Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplantation, 8, 51 58.
221. Truitt, R.L., Shih, C.Y., Lefever, A.V., Tempelis, L.D., Andreani, M. Bortin, M.M. (1983) Characterization of alloimmunization-induced T lymphocytes reactive against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo. Journal of Immunology, 131, 2050 2058.
222. Tse, W. Laughlin, M. (2005) Cord blood transplantation in adult patients. Cytotherapy, 7, 228 242.
223. Uckert, W. Schumacher, T.N. (2009) TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008. Cancer Immunology, Immunotherapy, 58, 809 822.
224. Ueno, N.T., Cheng, Y.C., Rondon, G., Tannir, N.M., Gajewski, J.L., Couriel, D.R., Hosing, C., de Lima, M.J., Anderlini, P., Khouri, I.F., Booser, D.J., Hortobagyi, G.N., Pagliaro, L.C., Jonasch, E., Giralt, S.A. Champlin, R.E. (2003) Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood, 102, 3829 3836.
225. Uhlin, M., Okas, M., Karlsson, H., Gertow, J., Henningsohn, L., Ringden, O., Karre, K., Levitsky, V. Mattsson, J. (2009) Increased frequency and responsiveness of PSA-specific T cells after allogeneic hematopoetic stem-cell transplantation. Transplantation, 87, 467 472.
226. Uzunel, M., Mattsson, J., Jaksch, M., Remberger, M. Ringden, O. (2001) The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. Blood, 98, 1982 1984.
227. Vandenberghe, P., Verhoef, G.E., Emonds, M.P., Demuynck, H., Zachee, P., De Wolf-Peeters, C., Decorte, R., Cassiman, J.J. Boogaerts, M.A. (1997) A single course of remission reinduction chemotherapy for acute myelogenous leukemia relapsing after allogeneic bone marrow transplantation is complicated by graft-versus-host disease and followed by sustained complete remission. Leukemia, 11, 1775 1778.
228. Vera, J., Savoldo, B., Vigouroux, S., Biagi, E., Pule, M., Rossig, C., Wu, J., Heslop, H.E., Rooney, C.M., Brenner, M.K. Dotti, G. (2006) T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood, 108, 3890 3897.
229. Verdonck, L.F., Lokhorst, H.M., Dekker, A.W., Nieuwenhuis, H.K. Petersen, E.J. (1996) Graft-versus-myeloma effect in two cases. Lancet, 347, 800 801.
230. Verdonck, L.F., Petersen, E.J., Lokhorst, H.M., Nieuwenhuis, H.K., Dekker, A.W., Tilanus, M.G. de Weger, R.A. (1998) Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells. Bone Marrow Transplantation, 22, 1057 1063.
231. Vigorito, A.C., Azevedo, W.M., Marques, J.F., Azevedo, A.M., Eid, K.A., Aranha, F.J., Lorand-Metze, I., Oliveira, G.B., Correa, M.E., Reis, A.R., Miranda, E.C. de Souza, C.A. (1998) A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplantation, 22, 1145 1151.
232. Wang, W., Meadows, L.R., den Haan, J.M., Sherman, N.E., Chen, Y., Blokland, E., Shabanowitz, J., Agulnik, A.I., Hendrickson, R.C., Bishop, C.E. et al (1995) Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science, 269, 1588 1590.
233. Warren, E.H., Greenberg, P.D. Riddell, S.R. (1998) Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood, 91, 2197 2207.
234. Weaver, C.H., Clift, R.A., Deeg, H.J., Storb, R., Appelbaum, F.R., Bensinger, W., Doney, K., Hansen, J.A., Martin, P.O., Sanders, J., Sullivan, K.M., Thomas, E.D., Singer, J., Witherspoon, R. Buckner, C.D. (1994) Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia. Bone Marrow Transplantation, 14, 885 893.
235. Weiden, P.L., Flournoy, N., Thomas, E.D., Prentice, R., Fefer, A., Buckner, C.D. Storb, R. (1979) Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. New England Journal of Medicine, 300, 1068 1073.
236. Weiden, P.L., Sullivan, K.M., Flournoy, N., Storb, R. Thomas, E.D. (1981) Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. New England Journal of Medicine, 304, 1529 1533.
237. Wu, C.J., Yang, X.F., McLaughlin, S., Neuberg, D., Canning, C., Stein, B., Alyea, E.P., Soiffer, R.J., Dranoff, G. Ritz, J. (2000) Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. Journal of Clinical Investigation, 106, 705 714.
238. Yang, X.F., Wu, C.J., Chen, L., Alyea, E.P., Canning, C., Kantoff, P., Soiffer, R.J., Dranoff, G. Ritz, J. (2002) CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Research, 62, 5517 5522.
239. Yannelli, J.R., Hyatt, C., McConnell, S., Hines, K., Jacknin, L., Parker, L., Sanders, M. Rosenberg, S.A. (1996) Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. International Journal of Cancer, 65, 413 421.
240. Yoshida, H., Kusuki, S., Hashii, Y., Ohta, H., Morio, T. Ozono, K. (2009) Ex vivo-expanded donor CD4(+) lymphocyte infusion against relapsing neuroblastoma: a transient graft-versus-tumor effect. Pediatric Blood & Cancer, 52, 895 897.
241. Yu, J., Venstrom, J.M., Liu, X.R., Pring, J., Hasan, R.S., O'Reilly, R.J. Hsu, K.C. (2009) Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation. Blood, 113, 3875 3884.
242. Zetterquist, H., Mattsson, J., Uzunel, M., Nasman-Bjork, I., Svenberg, P., Tammik, L., Bayat, G., Winiarski, J. Ringden, O. (2000) Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia. Bone Marrow Transplantation, 25, 843 851.
243. Zetterquist, H., Hentschke, P., Thorne, A., Wernerson, A., Mattsson, J., Uzunel, M., Martola, J., Albiin, N., Aschan, J., Papadogiannakis, N. Ringden, O. (2001) A graft-versus-colonic cancer effect of allogeneic stem cell transplantation. Bone Marrow Transplantation, 28, 1161 1166. (Pubitemid 34082975)